NCT00800501COMPLETEDanonymous

A Double-blind, Randomised, Parallel Group Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis, Using an Implanted Catheter and SynchroMed® II Pump

Sponsor

Source record

Newron Sweden AB

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

sNN0029, Placebo

Indication / condition

AI-normalized

Amyotrophic Lateral Sclerosis

Intervention

Source record

sNN0029, Placebo

Related intelligence directories

Indication directory: Amyotrophic Lateral Sclerosis Modality directory: small molecule Target directory: sNN0029

Source & freshness

Source record

NCT ID

NCT00800501

Original source

ClinicalTrials.gov

Source last updated

Dec 06, 2011

Ingested at

Jun 18, 2026

Internal sync

Jun 18, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT00800501

Title

A Double-blind, Randomised, Parallel Group Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis, Using an Implanted Catheter and SynchroMed® II Pump

Sponsor

Newron Sweden AB

Status

COMPLETED

Phase

PHASE1

Condition raw

Amyotrophic Lateral Sclerosis

Condition normalized

Amyotrophic Lateral Sclerosis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

sNN0029, Placebo

Target normalized

sNN0029, Placebo

Interventions

sNN0029, Placebo

Public preview

Source record

This study is conducted to evaluate the safety and tolerability of the drug product sNN0029, containing the growth factor VEGF165, when administered directly into one of the fluid filled cavities in the brain using an implanted catheter and an implanted SynchroMed® II pump. Patients with Amyotrophic Lateral Sclerosis will be enrolled.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Double-blind, Randomised, Parallel Group Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis, Using an Implanted Catheter and SynchroMed® II Pump

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 18, 2026

NCT ID

NCT00800501

Status

COMPLETED

Phase

PHASE1

Sponsor

Newron Sweden AB

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedDec 06, 2011

Internal syncJun 18, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00800501

Indication

Amyotrophic Lateral Sclerosis

Modality

small molecule

Target

sNN0029, Placebo

Intervention

sNN0029, Placebo

Source record